Patents Examined by Daniel E. Kolker
  • Anti-TNF?-antibodies and functional fragments thereof
    Patent number: 10774140
    Abstract: The present invention relates to antibody molecules and functional fragments thereof, capable of binding to tumor necrosis factor alpha (TNF?), to processes for their production, and to their therapeutic uses.
    Type: Grant
    Filed: March 16, 2017
    Date of Patent: September 15, 2020
    Assignee: Numab Therapeutics AG
    Inventors: Tea Gunde, Sebastian Meyer
  • Affinity support and method for isolating immunoglobulin
    Patent number: 10766924
    Abstract: To provide an affinity support in which a binding property of a ligand to a target substance is improved. The affinity support contains a solid phase support and a protein ligand, wherein the protein ligand is represented by formula (1): R—R1 (1) wherein R represents a linker binding to the solid phase support, which contains a polyproline, and R1 represents a protein showing an affinity to immunoglobulin, and the R is bound to a C terminal or an N terminal of an amino acid sequence in R1.
    Type: Grant
    Filed: July 27, 2016
    Date of Patent: September 8, 2020
    Assignees: JSR CORPORATION, JSR LIFE SCIENCES CORPORATION
    Inventors: Takashi Ichii, Satoshi Nakamura, Jun-ichi Yasuoka, Kaori Itaya, Tomonori Shiotani
  • Anti-TNF-alpha-antibodies and functional fragments thereof
    Patent number: 10759852
    Abstract: The present invention relates to antibody molecules and functional fragments thereof, capable of binding to tumor necrosis factor alpha (TNF?), to processes for their production, and to their therapeutic uses.
    Type: Grant
    Filed: March 16, 2017
    Date of Patent: September 1, 2020
    Assignee: Numab Innovation AG
    Inventors: Tea Gunde, Sebastian Meyer
  • Anti-CD25 antibody agents
    Patent number: 10752691
    Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25. In particular, the present disclosure provides sequences of anti-human CD25 antibodies, which do not block the binding of CD25 to IL-2 or IL-2 signalling. Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical composition and methods of treatment, in particular for treating cancer.
    Type: Grant
    Filed: March 13, 2019
    Date of Patent: August 25, 2020
    Assignees: Tusk Therapeutics Ltd., Cancer Research Technology Limited
    Inventors: Anne Goubier, Beatriz Goyenechea Corzo, Josephine Salimu, Kevin Moulder, Pascal Merchiers, Mark Brown, Sergio Quezada, James Geoghegan, Bianka Prinz
  • IL-26 inhibitors
    Patent number: 10751416
    Abstract: The present invention relates to methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with interleukin 26 (IL-26), including inflammatory diseases, such as psoriasis and/or bacterial infections.
    Type: Grant
    Filed: July 13, 2016
    Date of Patent: August 25, 2020
    Assignees: CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS (CHUV), BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Michel Gilliet, Jeremy Di Domizio, Stephan Meller
  • Anti-CD25 antibody agents
    Patent number: 10745485
    Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25. In particular, the present disclosure provides sequences of anti-human CD25 antibodies, which do not block the binding of CD25 to IL-2 or IL-2 signalling. Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical composition and methods of treatment, in particular for treating cancer.
    Type: Grant
    Filed: March 13, 2019
    Date of Patent: August 18, 2020
    Assignees: Tusk Therapeutics Ltd., Cancer Research Technology Limited
    Inventors: Anne Goubier, Beatriz Goyenechea Corzo, Josephine Salimu, Kevin Moulder, Pascal Merchiers, Mark Brown, Sergio Quezada, James Geoghegan, Bianka Prinz
  • Anti-CD25 antibody agents
    Patent number: 10738125
    Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25. In particular, the present disclosure provides sequences of anti-human CD25 antibodies, which do not block the binding of CD25 to IL-2 or IL-2 signalling. Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical composition and methods of treatment, in particular for treating cancer.
    Type: Grant
    Filed: March 13, 2019
    Date of Patent: August 11, 2020
    Assignees: Tusk Therapeutics Ltd., Cancer Research Technology Limited
    Inventors: Anne Goubier, Beatriz Goyenechea Corzo, Josephine Salimu, Kevin Moulder, Pascal Merchiers, Mark Brown, Sergio Quezada, James Geoghegan, Bianka Prinz
  • Interferon-beta analog peptide
    Patent number: 10738097
    Abstract: An interferon-beta (IFN?) analog peptide including a plurality of amino acid substitutions in an amino acid sequence of IFN? as set forth in SEQ ID No. 4. The IFN? analog peptide may include a plurality of amino acid substitution in the amino acid sequence of IFN? in at least one position of 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 18, 19, 20, 21, 22, 23, 24, and combinations thereof, numbered in accordance with SEQ ID No. 4.
    Type: Grant
    Filed: October 4, 2018
    Date of Patent: August 11, 2020
    Inventors: Mansour Poorebrahim, Matin Asghari, Mohammad Hossein Nasr-Esfahani, Nima Sanadgol, Mohammad Foad Abazari, Maryam Nouri Aleagha, Hassan Askari, Solmaz Sadeghi
  • Use of caprylic acid precipitation for protein purification
    Patent number: 10738078
    Abstract: In certain embodiments, the invention provides a method of purifying a protein of interest from a mixture which comprises the protein of interest and one or more contaminants, comprising: a) subjecting the mixture to a first chromatography step; b) recovering the protein of interest in an elution solution; c) adding caprylic acid to the elution solution to form a contaminant precipitate; d) removing the contaminant precipitate from the elution solution; and e) subjecting the post-precipitated elution solution to a second chromatography column, thereby purifying the protein of interest.
    Type: Grant
    Filed: November 3, 2015
    Date of Patent: August 11, 2020
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Ji Zheng, Jue Wang
  • Methods to produce a human plasma-derived IgG preparation enriched in brain disease-related natural iggs
    Patent number: 10738107
    Abstract: The present invention provides, among other aspects, methods for the manufacture of plasma-derived immunoglobulin G compositions highly enriched for anti-brain disease related protein antibodies (e.g., anti-A?, anti-RAGE, and anti-?-synuclein antibodies). Advantageously, the methods provided do not affect the manufacturing processes or capabilities for producing plasma-derived IgG therapeutics. Plasma-derived IgG compositions that are highly enriched for anti-brain disease related protein antibodies (e.g., anti-A?, anti-RAGE, and anti-?-synuclein antibodies), as also provided here. Methods for the treatment of brain diseases and disorders by administration of plasma-derived IgG compositions highly enriched for anti-brain disease related protein antibodies (e.g., anti-A?, anti-RAGE, and anti-?-synuclein antibodies), are also provided.
    Type: Grant
    Filed: December 20, 2016
    Date of Patent: August 11, 2020
    Assignees: Baxalta Incorporated, Baxalta GmbH
    Inventors: Lucia Gnauer, Harald Arno Butterweck, Theresa Bauer, Alfred Weber, Wolfgang Teschner, Hans-Peter Schwarz
  • Engineered anti-TGF-? antibodies and antigen-binding fragments
    Patent number: 10730936
    Abstract: Antibodies or antigen-binding fragments thereof are engineered to bind Transforming Growth Factor-? (TGF?). TGF?-isoform selective antibodies or antigen-binding fragments thereof may selectively bind human TGF?1, compared to human TGF?2 and human TGF?3, or may selectively bind human TGF?3, compared to human TGF?1 and human TGF?2. The design of the antibodies or antigen-binding fragments thereof is facilitated by a co-crystal structure of a recombinant Fab fragment of GC1008 bound to TGF?2 and by another co-crystal structure of the scFv version of GC1008 bound to TGF?1.
    Type: Grant
    Filed: August 7, 2017
    Date of Patent: August 4, 2020
    Assignee: GENZYME CORPORATION
    Inventors: Ronnie Wei, Aaron Moulin, Magali Mathieu, Clark Pan, Sunghae Park, Huawei Qiu
  • Immunoglobulin-binding protein and affinity carrier using same
    Patent number: 10723769
    Abstract: Provided is an affinity chromatography carrier that maintains high immunoglobulin-binding capacity and high alkali resistance. An immunoglobulin-binding protein including at least one modified immunoglobulin-binding domain, the modified immunoglobulin-binding domain being a polypeptide consisting of an amino acid sequence of an immunoglobulin-binding domain selected from the group consisting of the B domain, Z domain, C domain, and variants thereof of Staphylococcus aureus protein A, in which at least one amino acid residue is inserted between positions corresponding to the 3-position and position 4 of the amino acid sequence of the B domain, Z domain or C domain.
    Type: Grant
    Filed: March 24, 2016
    Date of Patent: July 28, 2020
    Assignees: JSR CORPORATION, JSR LIFE SCIENCES CORPORATION
    Inventors: Jun-ichi Yasuoka, Takashi Ichii, Satoshi Nakamura, Tomonori Shiotani, Kaori Itaya
  • Immunoglobulin aggregate removal
    Patent number: 10723762
    Abstract: For the removal of high molecular weight compounds from recombinantly produced polypeptides generally chromatographic methods are employed. It has been found that underivatized controlled pore glass (uCPG) selectively binds high molecular weight compounds present in a solution. The purified polypeptide can be recovered e.g. from the flow through of a chromatography column containing uCPG as chromatography material. It has been found that this effect is pronounced at a pH value of about 4 to 6 in buffered solutions. With approximately 100 m2 to 150 m2 uCPG surface per g of polypeptide almost 80% to 95% of the high molecular weight compounds are removed with a yield of 80% to 90% of polypeptide.
    Type: Grant
    Filed: April 13, 2017
    Date of Patent: July 28, 2020
    Assignee: Hoffman-La Roche Inc.
    Inventors: Stefan Hepbildikler, Wolfgang Kuhne, Eva Rosenberg, Gerhard Winter
  • Neuroinvasion inhibitor
    Patent number: 10717781
    Abstract: The present inventors discovered that neural invasion is suppressed by inhibiting IL-6 in a model for neural invasion of pancreatic cancer, and completed the present invention. The present inventors also demonstrated that: an IL-6 receptor is expressed in cells of human pancreatic cancer cell lines; and IL-6 enhances the chemotactic and migratory activities and intracellular signaling of pancreatic cancer cells; and thus pancreatic cancer can be treated by inhibiting IL-6. Furthermore, the present inventors found that neural invasion of human pancreatic cancer can be suppressed, from the results of administering IL-6 inhibitors to neural invasion model mice.
    Type: Grant
    Filed: June 5, 2009
    Date of Patent: July 21, 2020
    Assignees: National Cancer Center, Chugai Seiyako Kabushiki Kaisha
    Inventors: Shuichi Mitsunaga, Atsushi Ochiai
  • Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
    Patent number: 10703809
    Abstract: Eculizumab, a humanized monoclonal antibody against C5 that inhibits terminal complement activation, showed activity in a preliminary 12-week open-label trial in a small cohort of patients with paroxysmal nocturnal hemoglobinuria (PNH). The present study examined whether chronic eculizumab therapy could reduce intravascular hemolysis, stabilize hemoglobin levels, reduce transfusion requirements, and improve quality of life in a double-blind, randomized, placebo-controlled, multi-center global Phase III trial. It has been found that eculizumab stabilized hemoglobin levels, decreased the need for transfusions, and improved quality of life in PNH patients via reduced intravascular hemolysis. Chronic eculizumab treatment appears to be a safe and effective therapy for PNH.
    Type: Grant
    Filed: February 28, 2020
    Date of Patent: July 7, 2020
    Assignee: Alexion Pharmaceuticals, Inc.
    Inventors: Leonard Bell, Russell P. Rother, Mark J. Evans
  • Modulation of charge variants in a monoclonal antibody composition
    Patent number: 10696735
    Abstract: Combinations of different chromatography modalities with particularly refined conditions significantly reduce acid charge variants in a preparation of monoclonal antibodies. The process for reducing acid charge variants utilizes a combination of anion exchange and hydrophobic interaction chromatography, followed by cation exchange chromatography polishing, whereby the levels of acidic or basic charge species of the monoclonal antibodies may be modulated to a desired level.
    Type: Grant
    Filed: January 21, 2016
    Date of Patent: June 30, 2020
    Assignee: Outlook Therapeutics, Inc.
    Inventors: Chris Yonan, Christine Caroselli, Wiphusanee Dendamrongvit, Scott Gangloff
  • Use of alkaline washes during chromatography to remove impurities
    Patent number: 10695693
    Abstract: In certain embodiments, the invention provides a method of purifying a protein of interest from a mixture which comprises the protein of interest and one or more contaminants, said method comprising: a) subjecting the mixture to a first chromatography matrix, wherein the protein of interest binds to the first chromatography matrix; b) contacting the first chromatography matrix with a first wash solution which has a pH of at least 9.0, and does not comprise arginine or an arginine derivative; and c) eluting the protein of interest from the first chromatography matrix into an elution solution.
    Type: Grant
    Filed: March 11, 2016
    Date of Patent: June 30, 2020
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Jue Wang, Neil E. Jaffe, Krina Patel
  • Secretory IgA compositions, methods of making and methods of use thereof
    Patent number: 10696734
    Abstract: Described herein is secretory IgA isolated from the intestinal luminal fluid and intestinal mucosal of animals such as pigs and cows. Also included are methods of isolating secretory IgA. The secretory IgA is useful in food compositions such as animal and human food compositions as well as pharmaceutical compositions to increase growth rate, improve feed efficiency, reduce gastrointestinal inflammation, reduce a risk of gastrointestinal infection in the animal, or a combination thereof.
    Type: Grant
    Filed: August 29, 2016
    Date of Patent: June 30, 2020
    Assignee: WISCONSIN ALUMNI RESEARCG FOUNDATION
    Inventors: Jordan Marshall Sand, Mark Eric Cook
  • Methods of identifying and treating subjects having acute respiratory distress syndrome
    Patent number: 10689703
    Abstract: The present invention is related to novel methods for categorizing and treating subjects having Acute Respiratory Distress Syndrome (ARDS).
    Type: Grant
    Filed: April 26, 2016
    Date of Patent: June 23, 2020
    Assignee: National Jewish Health
    Inventors: Jerry A. Nick, Kenneth C. Malcolm
  • Methods and compositions for modulating T-GM cell function
    Patent number: 10690666
    Abstract: Disclosed herein is a T-helper cell (“TH-GM” cell) that is regulated by IL-7/STAT5 and which secrete GM-CSF/IL-3. Also disclosed are methods and compositions for modulating TH-GM function for the treatment of, e.g., inflammatory disorders. Diagnostic and prognostic methods for specifically identifying TH-GM-mediated inflammatory disorders (e.g., rheumatoid arthritis), as distinct from and/or in addition to non-TH-GM-mediated (e.g., TNF-?-mediated) inflammatory disorders, are also provided.
    Type: Grant
    Filed: September 25, 2015
    Date of Patent: June 23, 2020
    Assignee: NATIONAL UNIVERSITY OF SINGAPORE
    Inventors: Fu Xin-Yuan, Wanqiang Sheng, Yongliang Zhang, Fan Yang